Related Experiment Video
Updated: Dec 7, 2025

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
Published on: January 17, 2025
Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation
Zhen Guo1, Lin Sun1, Bailing Li2
1Department of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Insights
COVID-19 patients on extracorporeal membrane oxygenation (ECMO) often experience hypercoagulability, leading to oxygenator thrombosis and bleeding complications. Current evidence does not support more aggressive anticoagulation strategies for these patients.
Area of Science:
- Critical Care Medicine
- Hematology
- Infectious Diseases
Background:
- Severe coronavirus disease 2019 (COVID-19) can necessitate extracorporeal membrane oxygenation (ECMO) for respiratory support.
- Coagulation abnormalities are frequently observed in COVID-19 patients, posing challenges for anticoagulation management during ECMO.
Purpose of the Study:
- To investigate the specific coagulation characteristics and anticoagulation management strategies in COVID-19 patients undergoing venovenous ECMO.
- To identify the incidence of bleeding and thrombotic complications in this patient population.
Main Methods:
- A retrospective observational study was conducted at a single center.
- Data from laboratory-confirmed severe COVID-19 patients receiving venovenous ECMO between January and May 2020 were analyzed.
- Anticoagulation management, monitoring, bleeding complications, and thrombotic events were assessed.
Main Results:
- Eight out of 667 COVID-19 patients required venovenous ECMO, with elevated D-dimer levels noted before and during support.
- ECMO circuit packs were replaced 13 times due to coagulation-related complications.
- Common complications included oxygenator thrombosis (7/8), various hemorrhages (tracheal, oronasal, thoracic, puncture sites, cannulation sites).
Conclusions:
- COVID-19 patients on ECMO exhibit common hypercoagulability and secondary hyperfibrinolysis.
- These coagulation derangements may increase the risk of thrombotic events and oxygenator failure.
- Insufficient evidence currently exists to advocate for more aggressive anticoagulation protocols in this cohort.
Objective:
To explore special coagulation characteristics and anticoagulation management in extracorporeal membrane oxygenation (ECMO)-assisted patients with coronavirus disease 2019 (COVID-19).
Design:
Single-center, retrospective observation of a series of patients.
Participants:
Laboratory-confirmed severe COVID-19 patients who received venovenous ECMO support from January 20-May 20, 2020.
Interventions:
This study analyzed the anticoagulation management and monitoring strategies, bleeding complications, and thrombotic events during ECMO support.
Measurements And Main Results:
Eight of 667 confirmed COVID-19 patients received venovenous ECMO and had an elevated D-dimer level before and during ECMO support. An ECMO circuit pack (oxygenator and tubing) was replaced a total of 13 times in all 8 patients, and coagulation-related complications included oxygenator thrombosis (7/8), tracheal hemorrhage (5/8), oronasal hemorrhage (3/8), thoracic hemorrhage (3/8), bleeding at puncture sites (4/8), and cannulation site hemorrhage (2/8).
Conclusions:
Hypercoagulability and secondary hyperfibrinolysis during ECMO support in COVID-19 patients are common and possibly increase the propensity for thrombotic events and failure of the oxygenator. Currently, there is not enough evidence to support a more aggressive anticoagulation strategy.
Related Concept Videos
Pulmonary Embolism III: Nursing Management
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care

